Development of a stated-preference instrument to prioritize treatment goals in recent onset schizophrenia

References

• DeLisi LE. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull 2008;34:312-21
   PubMed Web of Science ®Google Scholar
• Owens MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016;388:86-97
   PubMed Web of Science ®Google Scholar
• Maglione JE, Thomas SE, Jeste DV. Late-onset schizophrenia: do recent studies support categorizing LOS as a subtype of schizophrenia? Curr Opin Psychiatry 2014;27:173-8
   PubMed Web of Science ®Google Scholar
• Bergen SE, O’Dushlaine CT, Lee PH, et al. Genetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family history. Schizophr Res 2014;154:48-53
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report 2001: Mental Health – New Understanding, New Hope. Chapter 3, p. 33. Available at: http://www.who.int/whr/2001/en/whr01_en.pdf [Last accessed 21 February 2017]
   Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44
   Web of Science ®Google Scholar
• NICE. Psychosis and schizophrenia in adults: the NICE guideline on treatment and management, updated edition 2014. Available at: http://www.ncbi.nlm.nih.gov/books/NBK248060/pdf/Bookshelf_NBK248060.pdf; accessed 04 June 2017
   Google Scholar
• Llorca PM, Abbar M, Courtet P, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 2013,13:340
   PubMed Web of Science ®Google Scholar
• Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical-period hypothesis. Int Clin Psychopharmacol 1998;13(Suppl1):S31-S40
   Web of Science ®Google Scholar
• Karson C, Duffy RA, Eramo A, et al. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatr Dis Treat 2016;12:57-67
   PubMed Web of Science ®Google Scholar
• Caseiro O, Pérez-Iglesias R, Mata I, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res 2012;46:1099-105
   PubMed Web of Science ®Google Scholar
• Gask L, Coventry P. Person-centred mental health care: the challenge of implementation. Epidemiol Psychiatr Sci 2012;21:139-44
   PubMed Web of Science ®Google Scholar
• Deegan PE, Carpenter-Song E, Drake RE, et al. Enhancing clients’ communication regarding goals for using psychiatric medications. Psychiatric Services 2017;8:771-5
   Web of Science ®Google Scholar
• Stanghellini G, Bolton D, Fulford WKM. Person-centered psychopathology of schizophrenia: building on Karl Jaspers’ understanding of patient’s attitude toward his illness. Schizophr Bull 2013;39(2):287-294
   Google Scholar
• Lincoln C, McGorry PD. Pathways to care in early psychosis: clinical and consumer perspectives. In: McGorry PD, Jackson HJ, eds. The Recognition and Management of Early Psychosis: A Preventive Approach. Cambridge: Cambridge University Press, 2004:51-80
   Google Scholar
• Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011;14:403-13
   PubMed Web of Science ®Google Scholar
• Janssen E, Segal J, Bridges J. A framework for instrument development of a choice experiment: an application to type 2 diabetes. Patient 2016;9:465-79
   PubMedGoogle Scholar
• Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity – establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1 – eliciting concepts for a new PRO instrument. Value Health 2011;14:967-77
   PubMed Web of Science ®Google Scholar
• dosReis S, Ng X, Frosch E, et al. Using best–worst scaling to measure caregiver preferences for managing their child’s ADHD: a pilot study. Patient 2015;8:423-31
   PubMedGoogle Scholar
• Wittenberg E. Instrument development in choice experiments. Patient 2016;9:379-81
   PubMedGoogle Scholar
• Flynn TN, Louviere JJ, Peters TJ, Coast J. Best–worst scaling: what it can do for health care research and how to do it. J Health Econ 2007;26:171-89
   PubMed Web of Science ®Google Scholar
• Kinter E, Schmeding A, Rudolph I, et al. Identifying patient-relevant endpoints among individuals with schizophrenia: an application of patient centered HTA. Int J Tech Assess Health Care 2009;25:35-41
   PubMed Web of Science ®Google Scholar
• van Schalkwyk GI, Davidson L, Srihari V. Too late and too little: narratives of treatment disconnect in early psychosis. Psychiatr Q 2015;86:521-32
   PubMed Web of Science ®Google Scholar
• Eiring Ø, Landmark BF, Endre A, et al. What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders. BMJ 2015;5:e007848
   PubMed Web of Science ®Google Scholar
• Louviere J, Flynn TN, Marley AAJ. The BWS Object Case in Best–Worst Scaling: Theory, Methods, and Applications. Cambridge: Cambridge University Press, 2015
   Google Scholar
• Wild D, Grove A, Martin M, et al. ISPOR Task Force for Translation and Cultural Adaptation. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005;8:94-104
   PubMed Web of Science ®Google Scholar
• Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995;273:59-65
   PubMed Web of Science ®Google Scholar
• Sandelowski M. Focus on research methods: whatever happened to qualitative description? Res Nurs Health 2000;23:334-40
   PubMed Web of Science ®Google Scholar
• Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res 2005;15:1277-88
   PubMed Web of Science ®Google Scholar
• Rothman ML, Beltran P, Cappelleri JC, et al. Patient-reported outcomes: conceptual issues. Value Health 2007;10:S66-S75
   PubMed Web of Science ®Google Scholar
• Fischer E, Shumway M, Owen R. Priorities of consumers, providers, and family members in the treatment of schizophrenia. Psych Services 2002;53:724-9
   Web of Science ®Google Scholar
• Kinter E, Prior T, Carswell C, Bridges J. A comparison of two experimental design approaches in applying conjoint analysis in patient-centered outcomes research. Patient 2012;5:279-94
   PubMedGoogle Scholar
• Levitan B, Markowitz M, Mohamed A, et al. Patients’ preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv 2015;66:719-26
   PubMed Web of Science ®Google Scholar
• Bridges J, Slawik L, Schmeding A, et al. A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia. Health Expect 2013;16:164-76
   PubMed Web of Science ®Google Scholar
• Bridges J, Kinter E, Schmeding A, et al. Can patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks. Patient 2011;4:267-75
   PubMedGoogle Scholar
• Tolley C, Rofail D, Gater A, Lalonde JK. The feasibility of using electronic clinical outcomes assessments in people with schizophrenia and their informal caregivers. Patient Relat Outcome Meas 2015:6:91-101
   PubMedGoogle Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2015;5:9:43-62
   Google Scholar
• Mendel R, Traut-Mattausch E, Frey D, et al. Do physicians’ recommendations pull patients away from their preferred treatment options? Health Expect 2012;15:23-31
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics 2012;30:183-95
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LNP, Heselgrave RJ. The aim of antipsychotic medications: what are they and are they being achieved? CNS Drugs 1995;4:8-16
   Web of Science ®Google Scholar
• Awad AG, Voruganti LNP. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs 2013;27:625-36
   PubMed Web of Science ®Google Scholar